These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 21918649)
1. Low-dose naltrexone for pruritus in systemic sclerosis. Frech T; Novak K; Revelo MP; Murtaugh M; Markewitz B; Hatton N; Scholand MB; Frech E; Markewitz D; Sawitzke AD Int J Rheumatol; 2011; 2011():804296. PubMed ID: 21918649 [TBL] [Abstract][Full Text] [Related]
2. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients. Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210 [TBL] [Abstract][Full Text] [Related]
3. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis. Lee TH; Lee JS; Park S; Lee KA; Kim HS Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335 [TBL] [Abstract][Full Text] [Related]
4. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis. Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173 [TBL] [Abstract][Full Text] [Related]
5. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society. Taş YM; Derviş Hakim G; Keskinoğlu P; Kenar G; Yarkan H; Zengin B; Can G; Önen F; Akkoç N; Birlik M; Akarsu M Turk J Gastroenterol; 2019 Mar; 30(3):234-241. PubMed ID: 30541712 [TBL] [Abstract][Full Text] [Related]
6. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600 [TBL] [Abstract][Full Text] [Related]
7. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655 [TBL] [Abstract][Full Text] [Related]
8. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis. Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0. Ozeri D; Peretz S; Oppenheim A; Watad A; Lidar M; Braun-Moscovici Y J Scleroderma Relat Disord; 2023 Feb; 8(1):31-35. PubMed ID: 36743811 [TBL] [Abstract][Full Text] [Related]
10. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch. Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228 [TBL] [Abstract][Full Text] [Related]
11. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S; Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Bae S; Allanore Y; Coustet B; Maranian P; Khanna D Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213 [TBL] [Abstract][Full Text] [Related]
18. The assessment of malnutrition and severity of gastrointestinal disease by using symptom-based questionnaires in systemic sclerosis: is it related to severe organ involvement or capillary rarefaction at microcirculation? Yalcinkaya Y; Erturk Z; Unal AU; Kaymaz Tahra S; Pehlivan O; Atagunduz P; Direskeneli H; Inanç N Clin Exp Rheumatol; 2020; 38 Suppl 125(3):127-131. PubMed ID: 32141434 [TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. Volkmann ER; Hoffmann-Vold AM; Chang YL; Jacobs JP; Tillisch K; Mayer EA; Clements PJ; Hov JR; Kummen M; Midtvedt Ø; Lagishetty V; Chang L; Labus JS; Molberg Ø; Braun J BMJ Open Gastroenterol; 2017; 4(1):e000134. PubMed ID: 28761687 [TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal symptom severity and progression in systemic sclerosis. van Leeuwen NM; Boonstra M; Fretheim H; Brunborg C; Midtvedt Ø; Garen T; Molberg Ø; Huizinga TWJ; de Vries-Bouwstra JK; Hoffman-Vold AM Rheumatology (Oxford); 2022 Oct; 61(10):4024-4034. PubMed ID: 35238377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]